In Response: We welcome the interest of Drs. Bara and Forgue-Lafitte in our publication (1). There are two issues that we will address. The first and more clinically relevant is that the PAM4-reactive epitope seems to be a highly specific biomarker for pancreatic adenocarcinoma. We have presented considerable data, including immunohistochemical studies of tissue specimens presented in this and prior publications (1, 2), as well as results from immunoassays of patient sera (3), to show that monoclonal antibody (mAb) PAM4 is reactive with a biomarker, the presence of which provides high diagnostic likelihood of pancreatic neoplasia. Furthermore, we determined that PAM4, although not reactive with normal adult pancreas or active pancreatitis, is reactive with the earliest stages of neoplastic progression within the pancreas, PanIN-1 and IPMN, and remains at high levels of expression throughout the progression to invasive pancreatic adenocarcinoma (1). This specificity of PAM4 serves as the basis for studying the diagnostic value of PAM4 imaging (4-6) and its therapeutic efficacy as a radiolabeled antibody (7).
such as MUC5ac. Although several counter-arguments can be made, based on the data from gene transfection studies, as well as physicochemical data presented in our original report on the generation of PAM4 (2), the information available at the time strongly supported the view that the PAM4 epitope is present on MUC1.
Drs. Bara and Forgue-Lafitte reference several publications, in particular the TD-4 Workshop (1997) of ISOBM (9) , to indicate that MUC1, as detected by several different mAbs, is located in epithelial cell membranes both in normal tissues and in early PanIN lesions, and that its presence in the cytoplasm within PanIN-3 and invasive neoplasia is regarded as a biomarker of malignancy. Such mAbs may react with different MUC1 epitopes (or cross-react with other mucins) that may or may not be expressed by individual tissue specimens. In fact, the cited reference used only a single specimen of ileum and breast along with two specimens of colon to perform the immunohistochemical studies. Although Drs. Bara and Forgue-Lafitte are correct that many of the anti-MUC1 mAbs showed membrane staining of these normal tissues, it is also true that many of the mAbs were unreactive with one or more of the tissues, with the well-studied anti-MUC1 mAb, SM3 (10), being negative with all of the tissues examined. Mucins are complex molecules that exhibit high levels of microheterogeneity (e.g., vntr, gene-splice variants, glycosylation status). Thus, many anti-MUC1 (or other mucin) antibodies identify cell surface, membrane, and/or cytoplasmic labeling of the respective mucin species, based on the biosynthetic mechanisms operative within the individual tissue specimen. PAM4 is reactive with both cytoplasmic and/or cell surface (apparent membrane) mucin, dependent on the individual tissue specimen, as was the MA5 anti-MUC1 antibody that was used as a control but that recognizes a different epitope.
With more recent data demonstrating the PAM4 epitope within normal gastric mucosa and the distribution of PAM4 within the cancer precursor lesions, we specifically made note of the similarity to MUC5ac (1). We are in agreement that PAM4 should be tested for immunoreactivity with recombinant MUC5ac apomucin as well as other recombinant mucin structures, and this is the focus of ongoing studies. Aside from such further characterizations, the principal interest is how to best apply PAM4 to the improved early detection and therapy of pancreatic carcinoma.
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